[go: up one dir, main page]

PE20061106A1 - Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida - Google Patents

Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida

Info

Publication number
PE20061106A1
PE20061106A1 PE2006000270A PE2006000270A PE20061106A1 PE 20061106 A1 PE20061106 A1 PE 20061106A1 PE 2006000270 A PE2006000270 A PE 2006000270A PE 2006000270 A PE2006000270 A PE 2006000270A PE 20061106 A1 PE20061106 A1 PE 20061106A1
Authority
PE
Peru
Prior art keywords
quinazolin
oxo
isopropylacetamide
ilpropoxi
propoxi
Prior art date
Application number
PE2006000270A
Other languages
English (en)
Inventor
Jeffrey Letourneau
Jui-Hsiang Chan
Patrick Jokiel
John Richard Morphy
Christopher Riviello
Susan Elizabeth Napier
Irina Neagu
Michael Ohlmeyer
Koc-Kan Ho
Original Assignee
Pharmacopeia Drug Discovery
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Drug Discovery, Organon Nv filed Critical Pharmacopeia Drug Discovery
Publication of PE20061106A1 publication Critical patent/PE20061106A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES ALQUILO C1-C6, CICLOALQUILO C3-C6, ALQUENILO C2-C6, ENTRE OTROS; R2 ES ARILO C6-C10, CICLOALQUILO C4-C7, HETEROARILO DE 5-10 MIEMBROS COMPRENDIENDO UN HETEROATOMO SELECCIONADO ENTRE N, O, S; R3 ES H, ALQUILO C1-C6, ALQUILOXILO C1-C6, HALOGENOS, ENTRE OTROS; R4 ESTA UBICADO EN LA POSICION 6 O 7 DEL ANILLO QUINAZOLINA; R4 ES DE PREFERENCIA 1-PROPOXIPIPERIDIN, 4-HIDROXIPIPERIDIN-1IL-PROPOXI, 3-AZEPAN-1-IL-PROPOXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[2-(3-CLORO-4-FLUOROFENIL)-4-OXO-6-(3-PIPERIDIN-1-1ILPROPOXI)-4H-QUINAZOLIN-3-IL]-N-ISOPROPILACETAMIDA; 2-[2-(4-FLUORO-3-METOXIFENIL)-4-OXO-6-(3-PIPERIDIN-1-ILPROPOXI)-4H-QUINAZOLIN-3-IL]-N-ISOPROPILACETAMIDA; (S)-(+)-2-[2-(3-CLOROFENIL)-6-(2-METIL-3-PIRROLIDIN-1-ILPROPOXI)-4-OXO-4H-QUINAZOLIN-3-IL]-N-ISOPROPILACETAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS SELECTIVOS V3, SIENDO UTILES EN EL TRATAMIENTO O PREVENCION DE ESTADOS DEPRESIVOS
PE2006000270A 2005-03-11 2006-03-09 Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida PE20061106A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66092605P 2005-03-11 2005-03-11
US71587505P 2005-09-09 2005-09-09

Publications (1)

Publication Number Publication Date
PE20061106A1 true PE20061106A1 (es) 2006-10-13

Family

ID=36579595

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000270A PE20061106A1 (es) 2005-03-11 2006-03-09 Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida

Country Status (18)

Country Link
US (1) US7807686B2 (es)
EP (1) EP1861380B1 (es)
JP (1) JP4997391B2 (es)
KR (1) KR20080009076A (es)
AR (1) AR052943A1 (es)
AT (1) ATE473214T1 (es)
AU (1) AU2006221962A1 (es)
CA (1) CA2599511C (es)
DE (1) DE602006015293D1 (es)
ES (1) ES2346790T3 (es)
IL (1) IL185343A0 (es)
MX (1) MX2007011023A (es)
NO (1) NO20074275L (es)
NZ (1) NZ560958A (es)
PE (1) PE20061106A1 (es)
RU (1) RU2007137649A (es)
TW (1) TW200643015A (es)
WO (1) WO2006095014A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
MX2009002685A (es) 2006-09-11 2009-10-13 Organon Nv Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il).
ATE523500T1 (de) * 2006-09-11 2011-09-15 Organon Nv Chinazolinon- und isochinolinon-acetamid-derivate
WO2008071779A1 (en) 2006-12-13 2008-06-19 N.V. Organon V3 antagonists for the treatment or prevention of chronic pain
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
JP5369721B2 (ja) * 2009-01-30 2013-12-18 大正製薬株式会社 ピリドピリミジン−４−オン誘導体
EA025824B1 (ru) 2009-07-27 2017-02-28 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
WO2011091407A1 (en) * 2010-01-25 2011-07-28 Glaxosmithkline Llp Trpv4 antagonists
ES2529119T3 (es) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
CA2812718C (en) * 2010-09-27 2018-11-27 E. I. Du Pont De Nemours And Company Method for preparing 2-amino-n-(2,2,2-trifluoroethyl)acetamide
DK2623499T3 (da) 2010-10-01 2015-06-08 Taisho Pharmaceutical Co Ltd 1,2,4-triazolonderivat
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
NO3175985T3 (es) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
WO2013062027A1 (ja) 2011-10-27 2013-05-02 大正製薬株式会社 アゾール誘導体
WO2013147117A1 (ja) 2012-03-30 2013-10-03 大正製薬株式会社 縮環アゾール誘導体
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
MX388781B (es) * 2015-07-22 2025-03-20 Araxes Pharma Llc Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c.
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
AU2016355433C1 (en) 2015-11-16 2021-12-16 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
PT3386591T (pt) 2015-12-09 2020-10-01 Cadent Therapeutics Inc Moduladores de recetores nmda heteroaromáticos e suas utilizações
ES2950348T3 (es) 2015-12-09 2023-10-09 Novartis Ag Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos
WO2018119374A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics Nmda receptor modulators and uses thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
EP3630745A2 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Covalent inhibitors of kras
AU2019312670B2 (en) 2018-08-01 2025-01-02 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
IL280474B2 (en) 2018-08-03 2023-09-01 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2506767A1 (fr) 1981-05-26 1982-12-03 Synthelabo Derives heterocycliques d'amidoximes, leur preparation et leur application en therapeutique
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2842527B1 (fr) 2002-07-19 2005-01-28 Sanofi Synthelabo Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives

Also Published As

Publication number Publication date
NZ560958A (en) 2009-09-25
JP4997391B2 (ja) 2012-08-08
KR20080009076A (ko) 2008-01-24
IL185343A0 (en) 2008-02-09
CA2599511A1 (en) 2006-09-14
RU2007137649A (ru) 2009-04-20
AU2006221962A1 (en) 2006-09-14
ATE473214T1 (de) 2010-07-15
EP1861380B1 (en) 2010-07-07
AR052943A1 (es) 2007-04-11
NO20074275L (no) 2007-09-27
US20080214553A1 (en) 2008-09-04
TW200643015A (en) 2006-12-16
CA2599511C (en) 2013-12-10
WO2006095014A1 (en) 2006-09-14
MX2007011023A (es) 2008-03-12
US7807686B2 (en) 2010-10-05
DE602006015293D1 (de) 2010-08-19
EP1861380A1 (en) 2007-12-05
JP2008532981A (ja) 2008-08-21
ES2346790T3 (es) 2010-10-20

Similar Documents

Publication Publication Date Title
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
PE20091095A1 (es) Moduladores de gamma secretasa
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20070141A1 (es) Derivados de isoquinolina como inhibidores de rho-cinasa
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
PE20110285A1 (es) Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20060648A1 (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
PE20050691A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
EA201000101A1 (ru) Производные пиримидина 934
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed